MorphoSys AG, a late-stage, biopharmaceutical company, announced that an affiliate of its licensee, Janssen Korea Ltd. (Janssen), reported that South Korea's Ministry of Food and Drug Safety has approved Tremfya (guselkumab) for the treatment of moderate to severe adult plaque psoriasis requiring phototherapy or systemic therapies.
Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen Research & Development, LLC and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology.
MorphoSys is eligible to receive royalties on net sales of Tremfya.
Dr. Markus Enzelberger, chief scientific officer of MorphoSys AG, said: "After recent approvals of Tremfya in Japan, Australia and Brazil as well as the approvals in the US, Canada and the European Union seen last year, we are very pleased about the Tremfya approval in South Korea. We expect Tremfya will continue to provide an important treatment option for patients living with moderate to severe plaque psoriasis on a truly global basis."
In addition to psoriasis, Tremfya is in phase 3 development for psoriatic arthritis. Janssen has announced plans to investigate Tremfya in Crohn's disease.
MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases.